AquaNab Develops Alpaca-Derived Nanoantibodies to Combat Sea Lice in Salmon Farming
AquaNab, a Hamburg-based biotech company, is tackling a significant challenge in salmon farming: sea lice, which cost the industry approximately $4 billion annually in treatment and losses. The company is developing tiny antibodies, known as nanoantibodies, derived from alpacas, which are intended to be delivered through fish feed to treat and prevent these parasites. Sea lice are notorious for their resilience, and traditional treatments often involve chemical baths and mechanical delousing, both of which can be stressful for the fish and are under increasing scrutiny from regulators concerned about chemical runoff and animal welfare.
The innovative aspect of AquaNab's approach lies in the use of nanoantibodies, which are small, stable antibodies produced by camelids like alpacas. AquaNab claims to be the first company to administer these antibodies orally to fish, mixed into their feed. This method is designed to allow the antibodies to survive the digestive process, cross the intestinal barrier, and enter the fish's bloodstream without the stress associated with conventional treatments.
The scientific foundation of this approach is robust. Dr. Alejandro Rojas, AquaNab's chief scientific officer, has a background in developing neutralizing nanobodies against SARS-CoV-2, while CEO Dr. Ruth Tamara Montero is a trained fish immunologist from Germany's Friedrich-Loeffler-Institut. Dr. Montero emphasizes that current treatments force producers to choose between expensive, stressful options and the losses incurred from sea lice infestations, and AquaNab aims to provide a viable alternative.
While the initial product targets Atlantic salmon, the founders envision a broader application of their technology, potentially addressing various bacterial, viral, and parasitic diseases across multiple farmed species. This vision has attracted investment, including funding from Finland’s Nordic Foodtech VC, marking its first investment outside the Nordic region.
Mika Kukkurainen, a partner at Nordic Foodtech, suggests that the concept of feed-based nanoantibody science could revolutionize health and resilience in food production, promising healthier animals and reduced losses. This innovation aligns with a growing trend in agriculture towards biological solutions rather than chemical interventions, as the industry seeks to enhance sustainability.
AquaNab's approach reflects a broader movement within aquaculture, which is exploring various methods to improve sustainability, including the use of insect protein in fish feed and even blockchain technology for tracking fish. The ultimate goal remains to feed a growing population with minimal environmental impact.
However, caution is warranted. AquaNab is still in the process of proving its concept, and the specifics of the investment remain undisclosed. Additionally, the commercial viability of delivering a novel biologic through feed raises questions about efficacy, cost, and regulatory pathways for treating food fish. The competition is fierce, as major animal health companies are also pursuing solutions to the sea lice problem, making it essential for AquaNab to demonstrate that its innovative idea can succeed in real-world conditions, not just in laboratory settings.




